Crystal Adam
President, R&D at TNGX; Chief Medical Officer at CCCC
- Sold, on record
- $9.5M
- Dollars the filings state
- Form 4 sales
- 19
- Latest Sep 1, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale TNGXRoutineMar 25, 2026 2026
Sold 12,000 shares at $20.11 ($241k)
Crystal Adam, President, R&D
10b5-1 planSold 9.6% of holdings ($2.5M position)112,622 shares left0.6x usual sizeFiling
- 2 Form 4 sale TNGXRoutineApr 1, 2026 +7 days
Sold 27,000 shares at $21.20 ($572k)
Crystal Adam, President, R&D
10b5-1 planSold 19.3% of holdings ($3M position)112,622 shares left1.5x usual sizeFiling
- 3 Form 4 sale TNGXRoutineApr 15, 2026 +14 days
Sold 38,460 shares at $25.00 ($962k)
Crystal Adam, President, R&D
10b5-1 planSold 25.5% of holdings ($3.8M position)112,622 shares left2x usual sizeFiling
- 4 Form 4 sale TNGXRoutineMay 1, 2026 +16 days
Sold 27,000 shares at $21.22 ($573k)
Crystal Adam, President, R&D
10b5-1 planSold 18.9% of holdings ($3M position)115,743 shares left1.3x usual sizeFiling
- 5 Form 4 sale TNGXRoutineJun 1, 2026 +31 days
Sold 27,000 shares at $22.88 ($618k)
Crystal Adam, President, R&D
10b5-1 planSold 18.9% of holdings ($3.3M position)115,743 shares left1.1x usual sizeFiling
- 6 Form 4 sale TNGXRoutineJul 1, 2026 +30 days
Sold 27,000 shares at $29.59 ($799k)
Crystal Adam, President, R&D
10b5-1 planSold 18.9% of holdings ($4.2M position)115,743 shares left1x usual sizeFiling
- 7 Form 4 sale TNGXRoutineAug 3, 2026 +33 days
Sold 27,000 shares at $27.24 ($736k)
Crystal Adam, President, R&D
10b5-1 planSold 18.9% of holdings ($3.9M position)115,743 shares left1x usual sizeFiling
- 8 Form 4 sale TNGXRoutineSep 1, 2026 +29 days
Sold 27,000 shares at $22.37 ($604k)
Crystal Adam, President, R&D
10b5-1 planSold 18.9% of holdings ($3.2M position)115,743 shares left1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (19)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Sep 3, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $604k | 18.9% | Routine | SEC |
| Aug 3, 2026 | Aug 5, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $736k | 18.9% | Routine | SEC |
| Jul 1, 2026 | Jul 2, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $799k | 18.9% | Routine | SEC |
| Jun 1, 2026 | Jun 3, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $618k | 18.9% | Routine | SEC |
| May 1, 2026 | May 5, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $573k | 18.9% | Routine | SEC |
| Apr 15, 2026 | Apr 16, 2026 | TNGX | President, R&D | Form 4 sale | 38,460 | $962k | 25.5% | Routine | SEC |
| Apr 1, 2026 | Apr 2, 2026 | TNGX | President, R&D | Form 4 sale | 27,000 | $572k | 19.3% | Routine | SEC |
| Mar 25, 2026 | Mar 27, 2026 | TNGX | President, R&D | Form 4 sale | 12,000 | $241k | 9.6% | Routine | SEC |
| Mar 5, 2026 | Mar 9, 2026 | TNGX | President, R&D | Form 4 sale | 20,251 | $304k | 15.2% | Routine | SEC |
| Feb 25, 2026 | Feb 27, 2026 | TNGX | President, R&D | Form 4 sale | 54,345 | $694k | 29.0% | Routine | SEC |
| Feb 3, 2026 | Feb 4, 2026 | TNGX | President, R&D | Form 4 sale | 18,452 | $226k | 9.0% | No plan | SEC |
| Feb 5, 2025 | Feb 6, 2025 | TNGX | Officer | Form 4 sale | 14,283 | $44k | 8.3% | No plan | SEC |
| Feb 7, 2024 | Feb 8, 2024 | TNGX | Officer | Form 4 sale | 8,371 | $105k | 6.5% | No plan | SEC |
| Nov 1, 2023 | Nov 2, 2023 | TNGX | Officer | Form 4 sale | 7,507 | $63k | 8.5% | No plan | SEC |
| Jan 4, 2022 | Jan 5, 2022 | CCCC | Chief Medical Officer | Form 4 sale | 15,000 | $475k | 50.0% | Unusual | SEC |
| Oct 1, 2021 | Oct 5, 2021 | CCCC | Chief Medical Officer | Form 4 sale | 15,000 | $681k | 100.0% | Unusual | SEC |
| Jul 29, 2021 | Aug 2, 2021 | CCCC | Chief Medical Officer | Form 4 sale | 15,000 | $675k | 100.0% | Unusual | SEC |
| Jul 1, 2021 | Jul 6, 2021 | CCCC | Chief Medical Officer | Form 4 sale | 15,000 | $570k | 100.0% | Unusual | SEC |
| Apr 5, 2021 | Apr 6, 2021 | CCCC | Chief Medical Officer | Form 4 sale | 15,000 | $567k | 100.0% | Unusual | SEC |